“We work systematically to strengthen our core business by delivering growth through the introduction of new products in existing markets and expanding products to new geographies. We have started and will continue the tedious process to increase company value by owning new products and brands. As a third step, we have been and will actively continue to source and evaluate M&A opportunities to deliver sustainable growth with the objective of building Navamedic to a leading Nordic pharmaceutical company with a footprint in North Europe and other selected countries,” says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
Stock exchange news
Navamedic ASA: Enters long term distribution agreement for PrecisionBiotics Zenflore® in the Nordics with Novozymes.
“We are proud to announce the agreement with Novozymes which expands our product portfolio within probiotics for specific disease areas Read more
Navamedic ASA: Q4 2020 financial results
“The fourth quarter of 2020 displayed strong growth in our underlying portfolio and new products introduced during the second half Read more
Navamedic ASA: Invitation to 2020 fourth quarter presentation
Navamedic ASA invites you to a presentation of the 2020 fourth quarter figures on Thursday February 18[th] at 08.30 CET. Due Read more
Meet us at exhibitions and fairs
Unfortunately, due to Covid-19. Exhibitions are postponed or cancelled until further notice.